

**REMARKS**

Claims 16, 18, 20, 22, 24, 42-47, 49-51, and 70-87 have been cancelled. Claims 1 and 2 have been amended. Claims 1-15, 17, 19, 21, 23, 25-41, 48, 52-69, 88-93 are currently pending. Claims 90-93 are withdrawn from consideration.

**1. New Restriction Requirement**

The Office Action requires additional restriction to one of the following Groups (I-II):

Group I: Claims 1-15, 17, 19, 21, 23, 25-41, 48, 52, 62-69, and 87-93 drawn to compounds where none of the substituents A, B, and D are attached to the carbon of the main nucleus of the compound through a "heteroaryl" value, and

Group II: Claims 1-1, 17, 19, 21, 23, 25-41, 48, 52, 62-69 and 87-93 in part and 16, 18, 22, 24, 42-47, 49-51, 53-61 and 70-86 in full where at least 1 of A, B, and/or B is attached to said carbon through a heteroaryl value.

In response, Applicants elect Group I.

**2. Rejection Under 35 U.S.C. 102 (b)**

Claims 1, 88, 90 and 92 are rejected under 35 U.S.C. 102(b) as being anticipated by WO02/04440. Applicants have amended claim 1 and limited "m" to "2" only. In view of this amendment, Applicants submit that the 102(b) rejection has been overcome.

**3. Rejection Under 35 U.S.C. 103(a)**

Claims 1, 88-93 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO98/28292. Applicants have amended claim 1 and limited "m" to "2" only. In view of this amendment, Applicants submit that the 103(a) rejection has been overcome.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification to such actions is earnestly sought. Should any issues in connection with the Office Action remain, the Examiner is invited to telephone the undersigned at (203)677-5644.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
203-677-5644

/ jennifer c chapman /  
Jennifer C. Chapman, Ph.D.  
Attorney for Applicants  
Reg. No. 47,487

Date: August 15, 2007